Results of Combined Pathogenetic Therapy in Netherton Syndrome: Clinical Case

Background. Netherton syndrome is a severe autosomal recessive disease based not only on genetically determined keratinization disorders, but also on immune system dysregulation.

Clinical case description. Boy K., 9 years old, diagnosed with severe atopic dermatitis and revealed Netherton syndrome during examinations. The dupilumab was administered due to the presence of severe polysensitization and clinical signs of allergic process. Wave-like course of the disease was observed during this therapy. Patient had acute exacerbation — generalized pustular rash — at the 7th month of treatment. The therapy with secukinumab was initiated according to the foreign literature on pathogenetic treatment of Netherton syndrome with interleukin (IL) 17 inhibitor. It has shown positive dynamics. Currently patient is administered with the combined therapy of IL-17 and IL-4/13 inhibitors with significant positive effect.

Conclusion. Genetically engineered biologic drugs targeting both the Th17 and Th2 have shown their efficacy in Netherton syndrome management.

1. Barbati F, Giovannini M, Oranges T, et al. Netherton Syndrome in Children: Management and Future Perspectives. Front Pediatr. 2021;9:645259. doi: https://doi.org/10.3389/fped.2021.645259

2. Shi ZR, Xu M, Tan GZ, et al. A case of Netherton syndrome with mutation in SPINK5 and FLG. Eur J Dermatol. 2017;27(5):536–537. doi: https://doi.org/10.1684/ejd.2017.3078

3. Petrova E, Hovnanian A. Advances in understanding of Netherton syndrome and therapeutic implications. Expert Opin Orphan Drugs. 2020;8(11):455–487. doi: https://doi.org/10.1080/21678707.2020.1857724

4. Paller AS, Renert-Yuval Y, Suprun M, et al. An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis. J Allergy Clin Immunol. 2017;139(1):152–165. doi: https://doi.org/10.1016/j.jaci.2016.07.019

5. Akiyama M. Understanding immune profiles in ichthyosis may lead to novel therapeutic targets. J Allergy Clin Immunol. 2022;149(4):1210–1212. doi: https://doi.org/10.1016/j.jaci.2022.02.010

6. Malik K, He H, Huynh TN, et al. Ichthyosis molecular fingerprinting shows profound T(H)17 skewing and a unique barrier genomic signature. J Allergy Clin Immunol. 2019;143(2):604–618. doi: https://doi.org/10.1016/j.jaci.2018.03.021

7. Barbieux C, Bonnet des Claustres M, Fahrner M, et al. Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN and allergic responses. J Allergy Clin Immunol. 2022;149(4): 1358–1372. doi: https://doi.org/10.1016/j.jaci.2021.08.024

8. Mazereeuw-Hautier J, Hernández-Martín A, O’Toole EA, et al, Management of congenital ichthyoses: European guidelines of care, part two. Br J Dermatol. 2019;180(3):484–495. doi: https://doi.org/10.1111/bjd.16882

9. Renner ED, Hartl D, Rylaarsdam S, et al. Comèl-Netherton syndrome defined as primary immunodeficiency. J Allergy Clin Immunol. 2009;124(3):536–543. doi: https://doi.org/10.1016/j.jaci.2009.06.009

10. Pontone M, Giovannini M, Filippeschi C, et al. Biological treatments for pediatric Netherton syndrome. Front Pediatr. 2022; 10:1074243. doi: https://doi.org/10.3389/fped.2022.1074243

11. Sübmuth K, Traupe H, Loser K, et al. Response to dupilumab in two children with netherton syndrome: improvement of pruritus and scaling. J Eur Acad Dermatol Venereol. 2021;35(2):e152-e155. doi: https://doi.org/10.1111/jdv.16883

12. Murase C, Takeichi T, Taki T, et al. Successful dupilumab treatment for ichthyotic and atopic features of netherton syndrome. J Dermatol Sci. 2021;102(2):126–129. doi: https://doi.org/10.1016/j.jdermsci.2021.03.003

13. Luchsinger I, Knöpfel N, Theiler M, et al. Secukinumab therapy for netherton syndrome. JAMA Dermatol. 2020;156(8):907–911. doi: https://doi.org/10.1001/jamadermatol.2020.1019

14. Blanchard SK, Prose NS. Successful use of secukinumab in netherton syndrome. JAAD Case Rep. 2020;6(6):577–578. doi: https://doi.org/10.1016/j.jdcr.2020.04.025

15. Herz-Ruelas ME, Chavez-Alvarez S, Garza-Chapa JI, et al. Netherton Syndrome: Case Report and Review of the Literature. Skin Appendage Disord. 2021;7(5):346–350. doi: https://doi.org/10.1159/000514699

16. Zingkou E, Pampalakis G, Sotiropoulou G. Cathelicidin represents a new target for manipulation of skin inflammation in Netherton syndrome. Biochim Biophys Acta Mol Basis Dis. 2020 10;1866(10):165831. doi: https://doi.org/10.1016/j.bbadis.2020.165831

17. Hovnanian A. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition. Cell Tissue Res. 2013;351(2): 289–300. doi: https://doi.org/10.1007/s00441-013-1558-1

18. Small AM, Cordoro KM. Netherton Syndrome Mimicking Pustular Psoriasis: Clinical Implications and Response to Intravenous Immunoglobulin. Pediatr Dermatol. 2016;33(3):e222–e223. doi: https://doi.org/10.1111/pde.12856

19. Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017; 140(1):109–120. doi: https://doi.org/10.1016/j.jaci.2016.08.056

20. Pfaff CM, Marquardt Y, Fietkau K, et al. The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function. Sci Rep. 2017;7(1):15631. doi: https://doi.org/10.1038/s41598-017-15892-7

21. Fukaura R, Akiyama M. Targeting IL-36 in Inflammatory Skin Diseases. BioDrugs. 2023;37(3):279–293. doi: https://doi.org/10.1007/s40259-023-00587-5

22. Swindell WR, Beamer MA, Sarkar MK, et al. RNA-Seq analysis of IL-1B and IL-36 responses in epidermal keratinocytes identifies a shared MyD88-dependent gene signature. Front Immunol. 2018;9:80. doi: https://doi.org/10.3389/fimmu.2018.00080

23. Müller A, Hennig A, Lorscheid S, et al. IkBz is a key transcriptional regulator of IL-36–driven psoriasis-related gene expression in keratinocytes. Proc Natl Acad Sci U S A. 2018;115(40): 10088–10093. doi: https://doi.org/10.1073/pnas.1801377115

24. Bakker DS, van der Wal MM, Heeb LEM, et al. Early and long-term effects of dupilumab treatment on circulating T-cell functions in patients with moderate-to-severe atopic dermatitis. J Invest Dermatol. 2021;141(8):1943e53.e13. doi: https://doi.org/10.1016/j.jid.2021.01.022

25. Grolleau C, Calugareanu A, Demouche S, et al. IL-4/IL-13 Inhibitors for Atopic Dermatitis Induce Psoriatic Rash Transcriptionally Close to Pustular Psoriasis. J Invest Dermatol. 2023;143(5): 711–721.e7. doi: https://doi.org/10.1016/j.jid.2022.10.015

26. Impellizzieri D, Ridder F, Raeber ME, et al. IL-4 receptor engagement in human neutrophils impairs their migration and extracellular trap formation. J Allergy Clin Immunol. 2019;144(1):267–279.e4. doi: https://doi.org/10.1016/j.jaci.2019.01.042

27. Onderdijk AJ, Baerveldt EM, Kurek D, et al. IL-4 downregulates IL-1b and IL-6 and induces GATA3 in psoriatic epidermal cells: route of action of a Th2 cytokine. J Immunol. 2015;195(4):1744–1752. doi: https://doi.org/10.4049/jimmunol.1401740

28. Foster AM, Baliwag J, Chen CS, et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J Immunol. 2014;192(12):6053–6061. doi: https://doi.org/10.4049/jimmunol.1301481